<DOC>
	<DOCNO>NCT01098656</DOCNO>
	<brief_summary>RATIONALE : Observation watch patient 's condition give treatment unless symptom appear change . Lenalidomide may stop growth cancer cell block blood flow cancer . It yet know whether observation lenalidomide effective treat patient complete partial response receive previous gemcitabine hydrochloride doxorubicin hydrochloride liposome cutaneous T-cell lymphoma mycosis fungoides/Sézary syndrome . PURPOSE : This randomized phase III trial study observation see well work compare lenalidomide treat patient complete partial response receive previous gemcitabine hydrochloride doxorubicin hydrochloride liposome stage IIB , stage III , stage IV cutaneous T-cell lymphoma stage IIB , stage III , stage IV mycosis fungoides/Sézary syndrome .</brief_summary>
	<brief_title>Lenalidomide Maintenance Post-debulking Advanced CTCL</brief_title>
	<detailed_description>OBJECTIVES : - To determine observation versus lenalidomide maintenance therapy debulking gemcitabine hydrochloride pegylated liposomal doxorubicin hydrochloride without radiotherapy prolongs progression-free survival patient advanced stage IIIB IV T-cell cutaneous lymphoma mycosis fungoides/Sézary syndrome previously treat intravenous chemotherapy . OUTLINE : This multicenter study . Patients stratify accord institution , response debulking treatment ( complete response v partial response ) , disease ( mycosis fungoides [ MF ] v erythrodermic MF/Sézary syndrome ) . Patients randomize 1 2 treatment arm . - Arm I : Beginning 4-6 week completion prior debulking therapy , patient undergo observation 560 day . - Arm II : Beginning 4-6 week completion prior debulking therapy , patient receive oral lenalidomide day day 1-21 . Treatment repeat every 28 day 20 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 week every 12 week thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnoses advance Tcell cutaneous lymphoma mycosis fungoides/Sézary syndrome Stage IIBIV disease Achieved complete partial response undergo prior debulking therapy 1 follow recommended* regimen without radiotherapy** : Gemcitabine hydrochloride IV 30 minute day 1 , 8 , 15 28day course dose 1,000 1,200 mg/m² total four course Pegylated liposomal doxorubicin hydrochloride IV 1 hour day 1 15 28day course dose 20 mg/m² total four course NOTE : *These recommend regimen alter accord local institutional policy . In case drug intolerance , study regimen switch one regimen . NOTE : **Local lowdose/energyionizing radiation therapy allow part debulking process treat lesion respond 3 course debulking chemotherapy . Sézary cell burden must decrease least 50 % debulking patient Sézary syndrome Disease appropriate skindirected therapy per local institution standard No disease progression registration randomization No CNS involvement PATIENT CHARACTERISTICS : WHO performance status 02 Life expectancy &gt; 12 month Hemoglobin ≥ 10 g/dL Absolute neutrophil count ≥ 1.5 x 10^9/L Platelet count ≥ 60 x 10^9/L Total bilirubin ≤ 1.5 time upper limit normal ( UNL ) Alkaline phosphatase ≤ 3 time UNL ALT/AST ≤ 3 time UNL Electrolytes ( include sodium , potassium , chloride ) normal Creatinine normal Creatinine clearance ≥ 60 mL/min Uric acid calcium normal Free T4 TSH ≤ 1.5 time ULN Patients buffer range normal value +/ 10 % hematology biochemistry acceptable Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 week prior , , 4 week completion study therapy Males must agree donate semen 1 week completion study therapy Patients high risk history thromboembolic event must agree receive prophylactic anticoagulation therapy ( e.g. , vitamin K ) keep INR range 23 No New York Heart Association class IIIIV disease No blood donate 1 week completion study therapy No uncontrolled infectious disease , autoimmune disease , immunodeficiency No second malignancy within past 3 year except surgically cure carcinoma situ cervix , situ breast cancer , incidental finding stage T1a T1b prostate cancer , basal squamous cell carcinoma skin No psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule No Lapp lactase deficiency history glucosegalactose malabsorption PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior intravenous chemotherapy cancer For purpose protocol , definition intravenous chemotherapy also include denileukin diftitox , antibody , antibody conjugate No prior splenectomy splenic irradiation No concurrent topical corticosteroid Concurrent systemic corticosteroid allow treatment tumor flare reactions No radiation drugbased therapy ( include steroid ) registration randomization No concurrent drug ( include steroid ) debulking regimen Lowdose steroid premedication allow investigator 's discretion No concurrent anticancer treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
</DOC>